Edition:
India

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

67.32USD
19 Jan 2018
Change (% chg)

$1.32 (+2.00%)
Prev Close
$66.00
Open
$65.94
Day's High
$67.35
Day's Low
$65.94
Volume
43,026
Avg. Vol
72,462
52-wk High
$67.35
52-wk Low
$25.92

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED.ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY "INTREPID" OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED.ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

Enanta Pharma Q4 earnings per share $1.86
Tuesday, 21 Nov 2017 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article

Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation
Friday, 30 Sep 2016 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation .According to FDA,BTD is intended to expedite development,review of an investigational therapy for serious condition.  Full Article

Enanta Pharmaceuticals Q3 loss per share $0.06
Tuesday, 9 Aug 2016 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal third quarter ended June 30, 2016 . Q3 loss per share $0.06 . Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S . Q3 revenue $14 million versus I/B/E/S view $13 million .U.S. FDA granted marketing approval for Abbvie's Viekira XR((TM))for treatment of genotype 1 hepatitis c virus.  Full Article

Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
Monday, 25 Jul 2016 

Abbvie Inc : CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C with compensated cirrhosis (child-pugh a) .Says VIEKIRAX with RBV is currently approved in European Union for GT4 patients with compensated cirrhosis for 24 weeks.  Full Article

Enanta pharmaceuticals Q2 loss per share $0.09
Tuesday, 10 May 2016 

Enanta Pharmaceuticals Inc : Enanta pharmaceuticals reports financial results for its fiscal second quarter ended march 31, 2016 . Q2 loss per share $0.09 . Q2 earnings per share view $0.10 -- Thomson Reuters I/B/E/S . Q2 revenue $13 million versus $57.4 million .Q2 revenue view $16.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated

* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE